ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
February 05, 2024 09:00 ET
|
ProLynx Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors...
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
November 09, 2023 05:30 ET
|
invIOs GmbH
Preclinical study will be conducted by Dr. David Reardon’s research groupImmune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer VIENNA, Austria and BOSTON,...
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical Officer
May 23, 2023 13:43 ET
|
Ivy Brain Tumor Center
Phoenix, Arizona, May 23, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical...
With 9.0% CAGR, Brain Tumor Drugs Market Size worth USD 4.43 Billion by 2029
December 16, 2022 01:17 ET
|
Fortune Business Insights
Pune, India, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The brain tumor drugs market size was valued at USD 2.31 billion in 2021 and USD 2.43 billion in 2022. The market is expected to reach USD 4.43 billion...
Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists
December 21, 2021 12:27 ET
|
Ivy Brain Tumor Center
Phoenix, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core...
Matt Tifft Joins Prestigious Forbes 30 Under 30 Class of 2022
December 03, 2021 09:00 ET
|
Live Fast Motorsports
MOORESVILLE, N.C., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Live Fast Motorsports co-owner Matt Tifft's career took a bit of a detour over the past few years, seeing the 25-year-old transition from the...
StacheStrong Raises $340,000 for the Ivy Brain Tumor Center’s Innovative Phase 0 Clinical Trial of Sonodynamic Therapy for Patients with Glioblastoma
December 01, 2021 13:08 ET
|
StacheStrong
VESTAL, NY, Dec. 01, 2021 (GLOBE NEWSWIRE) -- StacheStrong, a non-profit devoted to raising funds and awareness for brain cancer research, and Barrow Neurological Foundation, announced they raised...
NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma
January 12, 2021 10:10 ET
|
NX Development Corp.
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for...
NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)
November 17, 2020 14:12 ET
|
NX Development Corp.
Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
National Brain Tumor Society and the Brain Science Foundation Partner to Fund Research for Most Common Brain Tumor Type
February 19, 2019 12:12 ET
|
National Brain Tumor Society
Boston, MA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), a leading nonprofit dedicated to the brain tumor community in the United States, today announced a new partnership...